Evidence map›Paper›PMID 41035076›Full record

ArticleVirology journal2025

The antimicrobial peptide nisin promotes host cell survival during SARS-CoV-2 infection.

Bevin C English, Allan Radaic, Ross Barrios-Medina, Kerui Lin, Pachiyappan Kamarajan, Anita Sil, Yvonne L Kapila

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bevin C EnglishCoLabs, University of California San Francisco, San Francisco, CA, 94143, USA.
Allan RadaicSchool of Dentistry, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095-1668, USA.
Ross Barrios-MedinaSchool of Dentistry, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095-1668, USA.
Kerui LinSchool of Dentistry, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095-1668, USA.
Pachiyappan KamarajanSchool of Dentistry, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095-1668, USA.
Anita SilDepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, 94143-0414, USA.
Yvonne L KapilaSchool of Dentistry, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095-1668, USA. YKapila@dentistry.ucla.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 has been a major public health concern for the past five years. While remarkable work has been done to develop therapies, there is still a need for more treatments to fight this disease. Recently, it was suggested that nisin, an FDA-approved antimicrobial compound, may interfere with SARS-CoV-2 entry into host cells. Here, we show that nisin does not inhibit SARS-CoV-2 replication in vitro. Surprisingly, nisin treatment leads to reduced host-cell death during infection in a dose-dependent manner, suggesting that nisin may mitigate SARS-CoV-2-induced pathology.

Indexed as

Antimicrobial PeptidesAntiviral AgentsCOVID-19 Drug TreatmentNisinSARS-CoV-2AnimalsCell LineCell SurvivalChlorocebus aethiopsCOVID-19HumansVero CellsVirus InternalizationVirus ReplicationAntimicrobial PeptidesAntiviral AgentsNisinAntimicrobial peptideAntiviralBacteriocinCell deathNisinSARS-CoV-2

Identifiers

PMID41035076
PMCPMC12486997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.